Clinical Trials in Cromwell, Connecticut
15 recruiting
Showing 1–15 of 15 trials
Recruiting
Phase 3
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
Pediatric Migraine
Pfizer2,100 enrolled109 locationsNCT04649242
Recruiting
Phase 3
Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
Acute Treatment of Migraine
Pfizer600 enrolled64 locationsNCT04743141
Recruiting
Phase 2
Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis
Plaque Psoriasis
Oruka Therapeutics, Inc.160 enrolled27 locationsNCT07474792
Recruiting
Phase 3
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Major Depressive Disorder
Neurocrine Biosciences850 enrolled87 locationsNCT06966401
Recruiting
Phase 2
An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis
Plaque Psoriasis
Oruka Therapeutics, Inc.80 enrolled17 locationsNCT07449702
Recruiting
Phase 3
NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Major Depressive Disorder
Neurocrine Biosciences200 enrolled30 locationsNCT06963021
Recruiting
Phase 3
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)
Hidradenitis Suppurativa
Incyte Corporation550 enrolled107 locationsNCT06958211
Recruiting
Phase 2
Study to Assess the Adverse Events of Oral ABBV-932 in Adult Participants With Depressive Episodes Associated With Bipolar I or II Disorder
Bipolar I or II Disorder
AbbVie200 enrolled49 locationsNCT07220460
Recruiting
Phase 2
A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
Major Depressive Disorder (MDD)Major Depressive Disorder With Anxious Distress
Seaport Therapeutics360 enrolled45 locationsNCT07065240
Recruiting
Phase 3
Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research Design
Fibromyalgia
Axsome Therapeutics, Inc.620 enrolled16 locationsNCT07398417
Recruiting
Phase 2
Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder
Generalized Anxiety Disorder (GAD)
AbbVie315 enrolled52 locationsNCT06846320
Recruiting
Phase 2
Study of ABX-002 for the Adjunctive Treatment of Depressive Episodes Associated With Bipolar Disorder in Adults
Bipolar Disorder Depression
Autobahn Therapeutics, Inc.35 enrolled15 locationsNCT06869187
Recruiting
Phase 2
Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)
Major Depressive Disorder
Autobahn Therapeutics, Inc.230 enrolled50 locationsNCT06633016
Recruiting
Phase 3
Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol
Binge-Eating Disorder
Axsome Therapeutics, Inc.450 enrolled45 locationsNCT06413433
Recruiting
Phase 3
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
Major Depressive Disorder
Xenon Pharmaceuticals Inc.450 enrolled46 locationsNCT06775379